400 related articles for article (PubMed ID: 7850928)
21. Antitumor activity and cellular accumulation of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) monohydrate, in cisplatin-sensitive and -resistant murine P388 leukemia cells.
Kamisango K; Matsumoto T; Akamatsu K; Morikawa K; Tashiro T; Koizumi K
Jpn J Cancer Res; 1992 Mar; 83(3):304-11. PubMed ID: 1582895
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of five new platinum complexes having a glycolate leaving ligand.
Hong WS; Min YI; Kim HT; Cho YB; Kim KH; Kim DK
J Korean Med Sci; 1995 Aug; 10(4):269-74. PubMed ID: 8593207
[TBL] [Abstract][Full Text] [Related]
23. Effect of treatment schedule on antitumor activity of glycolate-0,0'-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II).
Suzumura Y; Kato T; Ueda R; Ota K
Anticancer Res; 1989; 9(4):1083-8. PubMed ID: 2817790
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of a new platinum complex, 2-aminomethyl-pyrrolidine (1, 1-cyclobutanedicarboxylato) platinum (II).
Endoh K; Akamatsu K; Matsumoto T; Morikawa K; Honda M; Mitsui H; Koizumi M; Koizumi K; Matsuno T
Anticancer Res; 1989; 9(4):987-91. PubMed ID: 2817826
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diammineglycolatoplatinum (254-S) and cis-diamminedichloroplatinum.
Koenuma M; Kasai H; Uchida N; Wada T; Hattori M; Oguma T; Totani T; Inaba M
Anticancer Res; 1995; 15(2):417-21. PubMed ID: 7763015
[TBL] [Abstract][Full Text] [Related]
29. Potent antitumour activity of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) against advanced L1210 leukaemia in mice.
Akamatsu K; Endo K; Matsumoto T; Kamisango K; Morikawa K; Koizumi M; Koizumi K
Br J Cancer; 1992 Nov; 66(5):827-32. PubMed ID: 1419625
[TBL] [Abstract][Full Text] [Related]
30. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
31. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
Jones M; Siracky J; Kelland LR; Harrap KR
Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
[TBL] [Abstract][Full Text] [Related]
32. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O
Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571
[TBL] [Abstract][Full Text] [Related]
33. Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes.
Khokhar AR; al-Baker S; Krakoff IH; Perez-Soler R
Cancer Chemother Pharmacol; 1989; 23(4):219-24. PubMed ID: 2647311
[TBL] [Abstract][Full Text] [Related]
34. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.
Tashiro T; Kawada Y; Sakurai Y; Kidani Y
Biomed Pharmacother; 1989; 43(4):251-60. PubMed ID: 2790145
[TBL] [Abstract][Full Text] [Related]
36. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
Akamatsu K; Saito H; Tsunenari T; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1993; 13(6A):2261-5. PubMed ID: 8297143
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
38. [Antitumor activity of platinum analogs against human ovarian tumors heterotransplanted into nude mice].
Sawada M; Ozaki M; Hongo J; Hirota Y; Inagaki M; Taniguchi H; Tateishi R; Mori Y
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):693-8. PubMed ID: 3548596
[TBL] [Abstract][Full Text] [Related]
39. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer.
Zang DY; Lee KH; Lee JS; Lee JH; Kim WK; Kim SH; Kim WD; Kim DS; Kim JH; Kim BS; Cho YB; Kim DK; Kim KH
Am J Clin Oncol; 1999 Oct; 22(5):495-8. PubMed ID: 10521066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
